Nervous System (e.g., Brain, Nerve, Etc.) Patents (Class 424/570)
  • Patent number: 10739777
    Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for generating a representation of a trajectory of a target agent in an environment. In one aspect, the representation of the trajectory of the target agent in the environment is a concatenation of a plurality of channels, where each channel is represented as a two-dimensional array of data values. Each position in each channel corresponds to a respective spatial position in the environment, and corresponding positions in different channels correspond to the same spatial position in the environment. The channels include a time channel and a respective motion channel corresponding to each motion parameter in a predetermined set of motion parameters.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 11, 2020
    Assignee: Waymo LLC
    Inventors: Khaled Refaat, Stephane Ross
  • Patent number: 9993564
    Abstract: A blood brain barrier shuttle comprising a brain effector entity and a brain targeting peptide.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 12, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Per-Ola Freskgard, Roland Schmucki, Eduard Urich
  • Patent number: 9655968
    Abstract: A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent. A medical package is also provided for baclofen delivery to patients suffering from spasticity.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: May 23, 2017
    Assignee: Wayne State University
    Inventors: Jay M. Meythaler, Stephen M. Tuel
  • Publication number: 20150079061
    Abstract: The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid.
    Type: Application
    Filed: July 14, 2014
    Publication date: March 19, 2015
    Inventors: Patrick J. Casey, Murray Hoare
  • Publication number: 20150079062
    Abstract: The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins. In one embodiment, the method includes lyophilizing the blast frozen component to remove at least some water from the blast frozen component thereby creating a freeze-dried form; and storing the lyophilized component; wherein the lyophilized component includes the proteins. The invention also provides a composition including proteins from at least one lyophilized, blast frozen component of a harvested mammalian feto-placental unit reconstituted with a fluid.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Patrick J. Casey, Murray Hoare
  • Patent number: 8968764
    Abstract: A keratin hydrogel matrix serves as an effective acellular scaffold for axonal regeneration and facilitates functional nerve recovery.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: March 3, 2015
    Assignee: Wake Forest University Health Sciences
    Inventor: Mark E. Van Dyke
  • Publication number: 20150030692
    Abstract: A method is described to treat chronic pain syndromes by treating extracorporeally a patient's cerebrospinal fluid (CSF). A patient's CSF is treated extracorporeally using a moiety that targets an antigen in the CSF. This moiety facilitates removal of the CSF antigen. The cleansed CSF is then returned to the patient.
    Type: Application
    Filed: March 19, 2013
    Publication date: January 29, 2015
    Inventor: Mitchell S. Felder
  • Publication number: 20150032045
    Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 29, 2015
    Inventors: Rafael Yuste, Roberto Etchenique, Luis Baraldo
  • Patent number: 8927276
    Abstract: The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: January 6, 2015
    Assignee: Cellin Technologies OUE
    Inventors: Kaia Palm, Toomas Neuman
  • Patent number: 8916339
    Abstract: A composition of neural tissue is made of spinal cord tissue harvested from a spinal cord of a mammal. The spinal cord tissue is harvested from vertebral column of the mammal. The spinal cord tissue is harvested post mortem. The mammal is one of a primate, an equine, a bovine, a porcine or other mammalian animal. The spinal cord tissue is dried or has the water content in the tissue reduced or eliminated by freeze drying or hypothermic dehydration.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: December 23, 2014
    Assignee: Vivex Biomedical, Inc.
    Inventor: Theodore I. Malinin
  • Publication number: 20140328940
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Joseph W. LEWCOCK, Christine Pozniak, Arundhati Sengupta-Ghosh
  • Patent number: 8748367
    Abstract: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: June 10, 2014
    Assignee: AS Faktor AB
    Inventors: Hans-Arne Hansson, Eva Jennische, Stefan Lange, Ivar Lönnroth, Peter Eriksson, Anders Persson
  • Patent number: 8703211
    Abstract: The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method for treatment and prophylaxis of cancer.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: April 22, 2014
    Assignee: Oy Neurofood AB
    Inventor: Thomas Tallberg
  • Patent number: 8685634
    Abstract: Disclosed herein are compositions and methods useful for preparing neural scaffolds. The scaffolds comprise tissue taken from the spinal cord and/or dura mater of vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: April 1, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Alan V. Boruch
  • Publication number: 20140088339
    Abstract: Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.
    Type: Application
    Filed: March 1, 2013
    Publication date: March 27, 2014
    Applicant: Francis Law Group
    Inventor: Robert Matheny
  • Publication number: 20140065238
    Abstract: The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-tem durability and function.
    Type: Application
    Filed: October 31, 2013
    Publication date: March 6, 2014
    Applicant: LifeNet Health
    Inventors: Lloyd Wolfinbarger, JR., Peny Lange, Alyce Linthurst-Jones, Eric Moore, Barry Naif
  • Publication number: 20140023722
    Abstract: Disclosed herein are compositions and methods useful for preparing neural scaffolds. The neural scaffold biomaterial comprises tissue taken from the spinal cord of a vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented.
    Type: Application
    Filed: July 20, 2012
    Publication date: January 23, 2014
    Inventor: Alan V. Boruch
  • Patent number: 8551476
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: October 8, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff
  • Publication number: 20130251670
    Abstract: Described are methods of treating macular edema, as well as other complications of ocular inflammation, through the administration of various stem cell populations and conditioned media thereof. In one embodiment a patient suffering from macular edema is administered an intramuscular dose of media conditioned by placental mesenchymal stem cells at a sufficient concentration and frequency to elicit a reduction in ocular inflammation. Other embodiments of the invention teach intra-ocular, intravenous, sublingual, and oral means of delivery conditioned media from various stem cell populations that has been optimized for anti-inflammatory, regenerative, and immune modulatory properties.
    Type: Application
    Filed: September 13, 2012
    Publication date: September 26, 2013
    Applicant: Aidan Products, Inc
    Inventors: Neil H. Riordan, Jorge Paz Rodriguez
  • Patent number: 8409624
    Abstract: The present invention provides an artificial cerebrospinal fluid containing 120 to 160 mEq/L of sodium ion, 1 to 6 mEq/L of potassium ion, 75 to 155 mEq/L of chloride ion, and 5 to 45 mEq/L of bicarbonate ion, and provides an artificial cerebrospinal fluid further containing at least one component selected from the group consisting of 10 g/L or less of a reducing sugar, 5 mmol/L or less of phosphoric acid, 5 mEq/L or less of calcium ion, and 5 mEq/L or less of magnesium ion. The artificial cerebrospinal fluid of the present invention can prevent or reduce the incidence of cerebral edema and can further suppress brain cell disorders when used as an irrigation fluid or perfusion fluid in the field of neurosurgery, such as intracranial surgery, or when used as a replenishing fluid for lost cerebrospinal fluid.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: April 2, 2013
    Assignee: Otsuka Pharmaceutical Factory, Inc.
    Inventors: Kazuhisa Doi, Yujiro Morioka, Takeshi Kawano
  • Publication number: 20130078314
    Abstract: The present invention is about a transdermal method that deliveries nutrients from fresh animal organs to the systemic circulation of the human body by applying the juice or chopped pieces of the fresh animal organs on the skin of the human body and allowing the nutrients to absorb through the layers of the exposed skin. The present invention aims to preserve the Yin and Yang energies naturally present in fresh organs and other foods that are lost in cooking and processing of foods. The present invention uses the full skin area transdermal delivery method by soaking the whole body in the juice of the fresh animal organs as well as the partial skin area transdermal delivery method by exposing certain parts of the human skin area to the fresh juices or chopped fresh animal organs and allowing the nutrients to enter the systemic circulation of the human body.
    Type: Application
    Filed: March 16, 2012
    Publication date: March 28, 2013
    Inventor: Peter Chan
  • Patent number: 8383098
    Abstract: An isolated multipotent neural stem cells has a phenotype identified by expression of the protein ?-tubulin IV and Olig2 and the absence of the proteins NG2, PLP, and GFAP.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: February 26, 2013
    Assignee: Case Western REserve University
    Inventors: Bruce Trapp, Robert Miller
  • Patent number: 8318136
    Abstract: Methods and systems are described that release one or both of a neurotrophin and an inhibitor of the degradation of the neurotrophin within or in the vicinity of a highly innervated tissue. In some embodiments, the method includes regulating the release of the neurotrophin and the inhibitor of degradation over time. In some embodiments, the method includes monitoring the concentration of the neurotrophin over time. The system may include a device or multiple devices for the release of the neurotrophin and the inhibitor as well as a controller. In some embodiments the system may include a sensor device and/or an imaging device capable of detecting the concentration of the neurotrophin over time. The release of the neurotrophin and inhibitor of degradation may be part of a controlled release system and regulated over time.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: November 27, 2012
    Assignee: The Invention Science Fund I, LLC
    Inventors: Muriel Y. Ishikawa, Edward K. Y. Jung, Lowell L. Wood, Jr.
  • Patent number: 8309057
    Abstract: Methods and systems are described that release one or both of a neurotrophin and an inhibitor of the degradation of the neurotrophin within or in the vicinity of a highly innervated tissue. In some embodiments, the method includes regulating the release of the neurotrophin and the inhibitor of degradation over time. In some embodiments, the method includes monitoring the concentration of the neurotrophin over time. The system may include a device or multiple devices for the release of the neurotrophin and the inhibitor as well as a controller. In some embodiments the system may include a sensor device and/or an imaging device capable of detecting the concentration of the neurotrophin over time. The release of the neurotrophin and inhibitor of degradation may be part of a controlled release system and regulated over time.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: November 13, 2012
    Assignee: The Invention Science Fund I, LLC
    Inventors: Muriel Y. Ishikawa, Edward K. Y. Jung, Lowell L. Wood, Jr.
  • Publication number: 20120231036
    Abstract: A medical device, said medical device, comprises: a first component having a non-biological material; a second component having a cloned biological material, said second component being attached to said first component, wherein said first component and said second component are operatively associated in a non-living medical device for at least one of treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. In another aspect, a method comprises: preparing a cloned biological material from a tissue or an organ; attaching said biological material to a medical device; interfacing said biological material with the non-biological material; providing treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism.
    Type: Application
    Filed: March 10, 2011
    Publication date: September 13, 2012
    Applicant: FIRST PRINCIPLES, INC.
    Inventor: Keith A. Raniere
  • Publication number: 20120195969
    Abstract: Disclosed are methods and compositions for treatment of acne or acneform conditions, particularly but not limited to, acne vulgaris with products generated from culture of stem or progenitor cells. Specifically, compositions of matter are disclosed which are useful for the treatment of acne and acne associated disease states, in particular acne vulgaris, by topical administration of products derived from stem cells or progenitor cells.
    Type: Application
    Filed: September 29, 2011
    Publication date: August 2, 2012
    Applicant: AIDAN RESEARCH AND CONSULTING, LLC
    Inventors: Neil H. Riordan, Tierney M. Riordan
  • Patent number: 8168749
    Abstract: A method of stimulating neurite outgrowth in a subject may include administering to the subject a formulation that includes a tctex-1-related polypeptide that stimulates neurite outgrowth in vitro.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: May 1, 2012
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Ching-Hwa Sung, Jen-Zen Chuang, Rajiv Ratan
  • Patent number: 8124131
    Abstract: A safe and widely-applicable food intake regulator can be provided by using at least one of a fish brain and parts thereof, which have the activity to regulate suppress food intake.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: February 28, 2012
    Assignee: Maruha Nichiro Foods, Inc.
    Inventors: Hiroyuki Enari, Masataka Kawarasaki
  • Patent number: 8110227
    Abstract: The central nervous system (CNS), i.e. the spinal cord and the brain, contains a large amount of various lipids, collectively called CNS lipids. These lipids are essential for embryonic induction but are also active in the adult body in keeping our cells in healthy normal function. By actively incorporating these normal vital CNS lipids in functional foodstuffs, it is possible to improve the immunity of a person by ingestion of such foodstuffs. The problem associated with the addition of brain substance to the diet is associated with bad taste and unpleasant attributes of the brain substance. The present invention discloses CNS lipids containing foodstuffs without the unpleasant taste and other attributes of the brain substance. The present invention relates to dairy based foodstuffs where normal fats and lipids have been replaced by CNS lipids.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: February 7, 2012
    Assignee: Oy Neurofood AB
    Inventor: Thomas Tallberg
  • Patent number: 8084425
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: December 27, 2011
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • Patent number: 8017124
    Abstract: Disclosed is the use of DMBT1, or of the nucleic acid encoding it, for the manufacture of a medicament for the treatment of a patient suffering from a disease caused by an agent, which possesses at least one accessible sulphate and/or at least one accessible phosphate group, uses of DMBT1 as a diagnostic for diagnosing the susceptibility of an individual to sulphate or phosphate groups, as well as methods for diagnosis, prophylaxis or treatment of diseases caused by an agent which possesses at least one accessible sulphate and/or at least one accessible phosphate group.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: September 13, 2011
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Jan Mollenhauer, Caroline End, Stephanie Blaich, Gaby Bergmann, Marcus Renner, Stefan Lyer, Rainer Wittig, Annemarie Poustka, Floris Bikker, Antoon Ligtenberg, Arie Nieuw-Amerongen, Enno Veerman
  • Patent number: 7998460
    Abstract: Methods are provided for protecting an individual from adverse long-term effects of neuroinflammation. Inflammatory blockade maintains neurogenesis capability after cranial irradiation by reducing the negative effects of activated microglia on neural precursor cells. These findings have broad implications for a variety of diseases of cognition, involving neuroinflammation and precursor cell dysfunction.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: August 16, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michelle L. Monje, Theo D. Palmer
  • Patent number: 7928059
    Abstract: Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of cartilage and bone damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: April 19, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ray Vanderby, Kelley W. Grorud
  • Patent number: 7892573
    Abstract: A keratin hydrogel matrix serves as an effective acellular scaffold for axonal regeneration and facilitates functional nerve recovery.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: February 22, 2011
    Assignee: Wake Forest University Health Sciences
    Inventor: Mark E. Van Dyke
  • Patent number: 7892751
    Abstract: A neurodegenerative disease or condition is diagnosed in a subject by obtaining a sample of cerebral spinal fluid from the subject and assaying the sample by an assay method that detects the presence of at least one antiphospholipid autoantibody in the sample, wherein an elevated level of at least one antiphospholipid autoantibody in the sample of cerebral spinal fluid correlates with a neurodegenerative disease or condition in the subject. The neurodegenerative disease or condition may also be diagnosed by assaying a sample of cerebral spinal fluid to detect nitrosylated antibodies, wherein an elevated level of nitrosylated antibodies correlates with a neurodegenerative disease or condition in said subject.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 22, 2011
    Assignee: Redox-Reactive Reagents LLC
    Inventor: John A. McIntyre
  • Patent number: 7883697
    Abstract: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: February 8, 2011
    Assignee: CHR-Hansen A/S
    Inventor: Bénédicte Flambard
  • Publication number: 20100310529
    Abstract: Isolated extracellular matrix from marrow adherent stromal cells and their descendents, which stimulates the growth and survival of a number of different neural cell types, is provided, along with methods for preparation and uses.
    Type: Application
    Filed: December 3, 2008
    Publication date: December 9, 2010
    Inventor: Irina Aizman
  • Patent number: 7838292
    Abstract: An isolated human olfactory stem cell can be prepared by culturing human tissue from olfactory neuroepithelium to form neurospheres.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: November 23, 2010
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Fred J. Roisen, Kathleen M. Klueber, Chengliang Lu
  • Patent number: 7824694
    Abstract: The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., a botulinum toxin, where the methods comprise a “wash-down” (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions relates to methods for enhancing the therapeutic effects of a neurotoxin for treating pain, e.g., headache pain.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: November 2, 2010
    Assignee: Allergan, Inc.
    Inventors: Eric R. First, Ryan A. Irvine
  • Patent number: 7803364
    Abstract: An isolated multipotent neural stem cells has a phenotype identified by expression of the protein ?-tubulin IV and Olig2 and the absence of the proteins NG2, PLP, and GFAP.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: September 28, 2010
    Assignee: The Cleveland Clinic Foundation
    Inventors: Bruce Trapp, Robert Miller
  • Publication number: 20100221224
    Abstract: The present invention is directed to a composition useful for making homogeneously mineralized self assembled peptide-amphiphile nanofibers and nanofiber gels. The composition is generally a solution comprised of a positively or negatively charged peptide-amphiphile and a like signed ion from the mineral. Mixing this solution with a second solution containing a dissolved counter-ion of the mineral and/or a second oppositely charged peptide amphiphile, results in the rapid self assembly of the peptide-amphiphiles into a nanofiber gel and templated mineralization of the ions. Templated mineralization of the initially dissolved mineral cations and anions in the mixture occurs with preferential orientation of the mineral crystals along the fiber surfaces within the nanofiber gel. One advantage of the present invention is that it results in homogenous growth of the mineral throughout the nanofiber gel.
    Type: Application
    Filed: June 22, 2009
    Publication date: September 2, 2010
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Samuel I. STUPP, Elia BENIASH, Jeffrey D. HARTGERINK
  • Patent number: 7771952
    Abstract: This invention relates to drug screening using mammalian repulsive guidance molecules and mammalian Neogenin. In addition, the invention provides for methods of preventing, alleviating or treating various disorders of the nervous system, angiogenic disorders or disorders of the cardio-vascular system and malignancies of different etiology by disrupting the interaction between RGM and Neogenin.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: August 10, 2010
    Assignee: Abott Laboratories
    Inventors: Stephen Strittmatter, Bernhard Mueller, Lutz Deitinghoff
  • Patent number: 7749496
    Abstract: A method of promoting neuronal regeneration includes administering an agent to at least one neural cell in contact with at least one neural cell growth inhibiting component in an amount effective to promote neuronal regeneration. The agent is selected from the group consisting of a Class I Rho family GTPase, a C1 activator, a Class II Rho family GTPase, and a C2 inhibitor.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Case Western Reserve University
    Inventors: Susann Brady-Kalnay, Ravi V. Bellamkonda
  • Patent number: 7638119
    Abstract: A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprises cells with induced antioxidant response element (ARE) mediated transcription, and (c) transplanting at least a portion of the cell culture into the brain of the patient, wherein symptoms of neurodegenerative disease are diminished.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: December 29, 2009
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jeffrey A. Johnson, Marcus J. Calkins
  • Patent number: 7632680
    Abstract: The invention is directed to the field of human stem cells and includes methods and compositions for isolating, propagating, and differentiating human stem cells. The invention provides therapeutic uses of the methods and compositions, including autologous transplantation of treated cells into humans for treatment of Parkinson's and other neuronal disorders.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: December 15, 2009
    Assignee: Levesque Biosciences, Inc.
    Inventors: Toomas Neuman, Michel Levesque
  • Publication number: 20090226536
    Abstract: Induction of neuronal fate in neural stem cells or neural progenitor or precursor cells, or other stem cells, and enhancement of induction of a specific neuronal phenotype, and particularly to induction and enhancement of induction of a midbrain dopaminergic neuronal phenotype. Expressing a nuclear receptor of the Nurr1 subfamily above basal levels within the cell, and regulating GSK-3? inhibition within the cell other than by means of a ligand for a Frizzled receptor.
    Type: Application
    Filed: September 2, 2005
    Publication date: September 10, 2009
    Inventors: Ernesto A. Arenas, Goncalo Castelo Branco, Nina Rawal
  • Publication number: 20090180965
    Abstract: The invention is directed to a method for treating a tissue or organ in a subject by directly administering an effective amount of an exogenous, decellularized extracellular matrix or a mixture of extracellular matrix and mesenchymal stem cells into the intended site of activity, such as bone marrow cavity. In one embodiment, the invention provides methods of treating bone marrow to increase the number of circulating progenitor and stem cells. In some other embodiments of the invention, the decellularized extracellular matrix to be directly administered is configured to be a time released therapeutic.
    Type: Application
    Filed: January 2, 2009
    Publication date: July 16, 2009
    Applicant: BOSTON SCIENTIFIC SCIMED, INC.
    Inventors: Toby M. Freyman, Wendy Naimark, Maria Palasis
  • Patent number: 7557182
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptide derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides. The present invention also relates to the use of these polypeptide for transporting a compound or drug across the blood-brain barrier of an individual and in the treatment and diagnosis of neurological diseases.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: July 7, 2009
    Assignee: Angiochem Inc.
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
  • Patent number: 7524934
    Abstract: A novel carboxypeptidase and the encoding gene thereof were successfully identified by screening a human hippocampus extract using brain-APP-cleaving activity as an index. Antibodies against the protein were also prepared. The antibodies are useful in, for example purifying the protein, or examining and diagnosing diseases, such as Alzheimer's disease, which cause accumulation of A? in the brain.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: April 28, 2009
    Inventor: Akira Matsumoto
  • Publication number: 20070248638
    Abstract: Methods are provided for producing a bioscaffold from natural tissues by oxidizing a decellularized tissue to produce a bioscaffold having pores therein. The pore size and porosity is increased to better accommodate intact cells so that live cells can better infiltrate and inhabit the bioscaffold. The bioscaffold may be freeze-dried or lyophilized, sterilized and (optionally) aseptically packaged for subsequent use. A further aspect of the present invention is a bioscaffold produced by the processes described herein. Methods of treatment using the bioscaffold as a graft or as a biomedical implant for implantation are also provided. Also provided are methods of seeding a bioscaffold with mammalian cells, wherein the seeding carried out either in vitro or in vivo, and wherein a bioscaffold produced as described herein is utilized for said seeding.
    Type: Application
    Filed: April 20, 2007
    Publication date: October 25, 2007
    Inventors: Mark E. Van Dyke, George J. Christ, Patrick W. Whitlock